April 18, 2019
TB Alliance and Mylan Announce Global Collaboration to Commercialize Investigational Drug Pretomanid as Part of Two Regimens to Treat Tuberculosis
Regimens under clinical development include treatment options for drug-resistant forms of TB
March 20, 2019
Statement on Building a Tuberculosis Free World: The Lancet Commission on Tuberculosis
This is an important moment to take stock of the milestones achieved in the fight against TB and to spur policymakers and funders to commit the necessary resources to end TB.
February 5, 2019
Compound Studied in TB to be Evaluated in the Treatment of Leishmaniasis
Wellcome commits £10 million to DNDi to develop new generation of oral drugs to treat leishmaniasis
January 23, 2019
Increased Commitment to Neglected Disease R&D, but TB Landscape Remains Largely Unchanged
Statement on 2018 G-FINDER Report
January 18, 2019
Played Red Dead Redemption 2? Here’s what you should know about TB
Whether it’s 1899 or 2019, TB is a serious disease that poses a significant challenge to global health
January 15, 2019
Jan Lundberg Joins TB Alliance Board of Directors
Lundberg has more than 20 years of experience in global R&D management, including the approval of 20+ new medicines
December 11, 2018
Schrödinger and TB Alliance Announce Collaboration to Accelerate Tuberculosis Drug Discovery
Partnership merges Schrödinger’s advanced modeling capabilities with TB Alliance’s expertise in tuberculosis biology to accelerate the development of next-generation treatments
December 4, 2018
Global TB Research Funding Continues to Fall Short
Statement on TAG Report on TB Research Funding Trends
November 28, 2018